Remove Engineering Remove Marketing Remove Molecular Biology
article thumbnail

Automated red blood cell exchange: bridging treatment gaps in sickle cell disease care

Drug Target Review

Dr Aaron Haubner, Senior Manager of North America Medical Affairs and Market Access at Terumo Blood and Cell Technologies , reveals that while promising new treatments emerge, urgent partnerships are needed to ensure this essential blood therapy reaches the patients who need it most.

Disease 52
article thumbnail

Levers for Biological Progress

Codon

I’ve chosen these two because I think they are the linchpin by which we’ll be able to build broadly useful AI models for cell and molecular biology. But looking ahead to the second bottleneck, what does it mean to say that biology is “complex”?

DNA 133
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inside ARIA, the UK's Bet to Build Scientific Revolutions

Codon

At Activate and Cyclotron Road, he built fellowships that served as perches for researchers working on societally important ‘ hard’ technologies that might not yet be VC-fundable find their feet and begin developing technologies into market-ready products. We can’t engineer that. Join Asimov Press.

article thumbnail

Issue 07 is Coming on Monday

Codon

Stories We Want to Publish Bottlenecks in Tree Engineering In 1903, John Krusback, the president of a local state bank in Wisconsin, decided that he was going to grow a chair. Today, companies like Living Carbon have advanced from grafting and molds and are using genetic engineering to produce trees that can photosynthesize more efficiently.

article thumbnail

Navigating the challenges of cell therapies

Drug Target Review

Ruella’s research indicated that the removal of CD5 from engineered T cell therapies resulted in increased cytotoxicity and improved anti-tumor efficacy in animal models. By harnessing the fundamental biology of T cells, Senza5 can be used to improve the efficacy of almost any CAR-T therapy.

Therapies 116
article thumbnail

How organoids can redefine pre-clinical research

Drug Target Review

The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 Engineering organoids. Human organoids: model systems for human biology and medicine.

article thumbnail

Advancing CAR-T therapy: how CD5 modulation is shaping cancer treatment

Drug Target Review

By simultaneously deleting CD5 and expressing a CD5-targeting CAR into engineered patient T cells, VIPER-101 offers a novel approach for treating T-cell lymphoma. Can you explain the key features and benefits of the Senza5 platform developed by Vittoria Biotherapeutics?